Acute cardiorenal syndrome in ICU · ICU Topics

Cinematic anatomical illustration of the heart and kidney linked by a raised central venous pressure and low forward flow, a dilated IVC and congested renal veins, clinical-blue lighting on dark background, medical educational, no text, no people — FigureThe cardiorenal syndrome — the venous congestion (the raised CVP) drives the AKI as much as the low output. The decongestion is the target; a creatinine rise during the effective diuresis is the acceptable and the prognostically favourable.

The five types of cardiorenal syndrome

The Ronco classification distinguishes five CRS subtypes by acuity (acute vs chronic) and direction (heart → kidney, kidney → heart, or systemic). Distinguishing the type drives both the workup and the therapy.[6][1]

The five types of cardiorenal syndrome (Ronco/Rangaswami classification)

Type	Name	Primary insult	Secondary effect	Setting	Typical ICU relevance
1	Acute cardiorenal	Acute heart failure / ACS / flash pulmonary oedema	AKI develops hours-days	ICU, ED, CCU	Highest — most encountered in ICU
2	Chronic cardiorenal	Chronic heart failure (HFrEF/HFpEF)	Progressive CKD	Outpatient, cardiology	Moderate — seen during exacerbations
3	Acute renocardial	AKI (contrast nephropathy, ATN, obstruction)	Acute heart failure (volume, K+, acidosis, uraemia)	ICU, nephrology	High — common in ICU AKI
4	Chronic renocardial	CKD / ESRD	Chronic heart failure (uraemic cardiomyopathy, LVH, vascular calcification)	Renal clinic, dialysis unit	Moderate — dialysis patients in ICU
5	Secondary (systemic)	Systemic disease (sepsis, diabetes, amyloid, SLE, cirrhosis)	Simultaneous heart AND kidney dysfunction	ICU, multisystem disease	High — sepsis is the prototype

[1]

Type 1 (acute cardiorenal) is the prototype ICU problem: a patient with acute decompensated heart failure (ADHF), flash pulmonary oedema or cardiogenic shock develops a rising creatinine within hours to days. The dominant driver is venous congestion raising renal interstitial pressure, compounded by low forward flow when output is impaired.[2][5]

Type 2 (chronic cardiorenal) describes the slow, progressive CKD that accompanies chronic HFrEF or HFpEF. Renal dysfunction here is a marker of advanced disease and predicts mortality; it is not, by itself, a reason for ICU admission unless the patient decompensates into a type 1 episode.[5]

Type 3 (acute renocardial) is renal-first: an AKI (post-contrast, ATN, obstructive, rhabdomyolysis) precipitates volume overload, hyperkalaemic arrhythmia, acidosis-driven myocardial depression, or uraemic pericarditis. Management is of the AKI first (fluids if hypovolaemic, K+ control, RRT for refractory overload/hyperkalaemia/acidosis).[1]

Type 4 (chronic renocardial) is the uraemic cardiomyopathy of CKD/ESRD — left ventricular hypertrophy, diastolic dysfunction, vascular and valvular calcification, accelerated atherosclerosis. Dialysis patients presenting to ICU have high cardiovascular mortality.[13]

Type 5 (secondary) is simultaneous heart and kidney injury from a systemic process: sepsis (the most common ICU cause — cytokine storm, microcirculatory failure, mitochondrial dysfunction), diabetes, amyloidosis, SLE, vasculitis, cirrhosis (hepatorenal plus cardiomyopathy). Treat the underlying disease; the heart and kidney recover together.[6]

Pathophysiology in depth

Venous congestion driving renal interstitial pressure and reduced GFR in type 1 cardiorenal syndrome — FigurePathophysiology of type 1 CRS — raised CVP raises renal venous and interstitial pressure and drops GFR as much as low forward flow; RAAS/sympathetic activation completes the vicious cycle.

CRS is not a single mechanism — it is a convergent disorder in which four overlapping pathways drive a self-reinforcing vicious cycle. Understanding which pathway dominates in a given patient directs therapy.[1][13]

1. Venous congestion — the dominant driver in decompensated HF

Elevated central venous pressure (CVP) is transmitted retrograde to the renal veins, raising renal interstitial and Bowman's capsule hydrostatic pressure. This compresses the peritubular capillaries and tubules, opposes glomerular filtration, and reduces the hydrostatic gradient that drives filtration — GFR falls even when renal arterial inflow is intact. The landmark Mullens/ESCAPE analyses showed CVP is the strongest haemodynamic predictor of worsening renal function in ADHF, stronger than cardiac output, ejection fraction, or systolic blood pressure. A CVP above ~12–14 mmHg is associated with a steep rise in AKI incidence; above ~18 mmHg AKI is nearly universal.[2][5]

This single insight underpins modern therapy: decongestion is the primary target, even when creatinine rises during diuresis — a congested patient with a slightly higher creatinine does better than a less-congested patient with a stable creatinine. [1]

2. Low forward flow — reduced renal perfusion

When cardiac output falls (cardiogenic shock, end-stage HFrEF, right ventricular failure), mean arterial pressure and renal perfusion fall. The kidney is vulnerable because it receives ~20% of cardiac output and because the afferent arteriole is supplied by relatively low-pressure flow. Reduced perfusion activates intrarenal autoregulation and, when MAP falls below ~65 mmHg, autoregulation fails and GFR drops sharply. Inotropes and vasopressors restore forward flow but at the cost of increased myocardial oxygen demand and arrhythmia risk — they are bridges, not destinations.[5]

3. Neurohormonal activation — the vicious cycle

Reduced renal perfusion and sympathetic sensing trigger the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS):

Angiotensin II → efferent arteriolar vasoconstriction (maintains GFR acutely — the basis for the ACEi/ARB creatinine rise), systemic vasoconstriction, aldosterone release, sodium retention, inflammation and fibrosis.
Aldosterone → distal sodium reabsorption, potassium/magnesium loss, myocardial fibrosis.
Sympathetic activation → vasoconstriction, tachycardia, renin release, arrhythmias. [1]

The cycle is self-reinforcing: each effector worsens both heart failure and renal perfusion, driving further activation. Breaking the cycle (vasodilators, ACEi/ARB/ARNI once stable, beta-blocker once stable, MRA, SGLT2 inhibitor) is the foundation of chronic disease modification.[5][13]

4. Inflammation, oxidative stress and endothelial dysfunction

Acute heart failure and AKI both release cytokines (TNF-α, IL-6), reactive oxygen species, and damage-associated molecular patterns that cross-talk between the two organs. Endothelial dysfunction reduces nitric oxide bioavailability in the renal vasculature, blunting the vasodilation that protects the kidney. This pathway is dominant in type 5 CRS (sepsis) but contributes to all types.[1]

5. Intra-abdominal hypertension (IAH) and the cardio-abdominal-renal syndrome

Severe congestion causes hepatic and bowel wall oedema, raising intra-abdominal pressure (IAP). IAH (IAP >12 mmHg) compresses the renal veins, the renal parenchyma, and the abdominal aorta/renal arteries, raising CVP and reducing renal perfusion simultaneously. A bladder pressure >20 mmHg with new organ dysfunction defines abdominal compartment syndrome — a reversible contributor to CRS that responds to decongestion and paracentesis/surgical decompression.[2]

Venous congestion vs low forward flow — two mechanisms, different therapy

Feature	Venous congestion dominant	Low forward flow dominant
Typical patient	ADHF, volume overload, raised JVP, oedema, hepatomegaly	Cardiogenic shock, cool peripheries, oliguria, low CO
CVP	High (>12–14 mmHg)	Variable — may be low or normal
Cardiac output	Preserved or high (warm, wet)	Low (cold, dry or cold, wet)
Blood pressure	Often high	Often low
Primary therapy	Decongestion — high-dose loop ± thiazide, nitrates	Restore output — inotrope, vasopressor, MCS
Creatinine on diuresis	May rise — continue if decongesting	Worsens with low flow — fix output
Prognostic marker	CVP is the strongest predictor of AKI	MAP, lactate, mixed venous saturation

[1]

Clinical assessment

CRS is a clinical diagnosis supported by bedside investigations. The single most important question is: is the patient congested (wet) or dry, and is perfusion adequate (warm) or impaired (cold)? The four haemodynamic profiles (wet/dry × warm/cold) drive therapy.[2]

Bedside assessment of congestion:

Jugular venous pressure — the single most useful bedside sign. Raised JVP = venous congestion.
Lung auscultation — crackles (but crackles may be absent in chronic HF).
Peripheral oedema, sacral oedema, ascites.
Hepatomegaly, hepatojugular reflux.
Lung ultrasound — B-lines (comet-tail artefacts) quantify extravascular lung water; multiple bilateral B-lines = interstitial pulmonary oedema.
Point-of-care echo — IVC size and collapsibility (a plethoric, non-collapsing IVC = high CVP); right heart assessment for pulmonary hypertension, RV failure, TR; LV systolic and diastolic function.
Daily weights — the most sensitive bedside measure of net fluid balance.
Hemodynamic monitoring — CVP (central line), arterial line for MAP; advanced monitors (PiCCO, pulmonary artery catheter) when peripheral perfusion or cardiac output is in question. [1]

Laboratory and imaging:

Urea, creatinine, eGFR, electrolytes (K+, Na+, Mg2+, phosphate), venous blood gas (lactate, acidosis).
Troponin (myocardial injury), NT-proBNP/BNP (heart failure severity — but BNP rises with renal dysfunction alone).
Urine sodium (low <30 mmol/L on diuretics suggests under-diuresis; FENa if pre-renal vs ATN unclear).
Urinalysis — bland in CRS; casts/proteinuria suggest intrinsic renal disease (type 3 or concurrent).
Echocardiography — EF, diastolic function, RV size and function, valvular lesions, pericardial effusion, IVC.
Renal ultrasound — to exclude obstruction (especially type 3), assess kidney size/corticomedullary differentiation for chronicity. [1]

Management of acute cardiorenal syndrome

Decongestion ladder with loop diuretics, sequential nephron blockade, vasodilators and SGLT2 inhibitors — FigureManagement ladder — decongest with high-dose loop ± thiazide sequential blockade and nitrates; accept a creatinine rise if congestion is clearing; reserve ultrafiltration for true diuretic failure (CARRESS-HF).

Management of acute cardiorenal syndrome (type 1)

Assess volume status and perfusion — clinical (JVP, oedema, crackles, hepatomegaly, peripheral temperature, capillary refill, urine output), ultrasound (IVC, B-lines), haemodynamics (CVP, MAP, cardiac output if monitored). Classify as WARM/WET, WARM/DRY, COLD/WET, COLD/DRY.
Decongest (primary target for wet patients) — HIGH-DOSE loop diuretics (frusemide IV — 2-2.5x oral dose). If inadequate: ADD thiazide (metolazone/hydrochlorothiazide — sequential nephron blockade). TARGET: 2-3 L negative balance/day (or adequate urine output). Monitor renal function — may rise, continue if congested
Optimise cardiac output (for cold patients) — if low output (cardiogenic shock): inotropes (dobutamine, milrinone). Vasopressors (noradrenaline) if MAP <65. Vasodilators (GTN infusion) if hypertensive and warm. Mechanical circulatory support (IABP, Impella, VA-ECMO) if refractory shock. Avoid hypotension (worsens renal perfusion)
Avoid nephrotoxins — STOP NSAIDs, ACEi/ARB/ARNI (temporarily if hypotensive), contrast (use pre-procedural hydration if unavoidable), aminoglycosides, iodinated contrast
Treat electrolyte derangements — replace K+ (IV/oral), Mg2+; manage hyponatraemia (fluid restriction, tolvaptan for severe); correct acidosis
Start disease-modifying therapy once stable — SGLT2 inhibitor (dapagliflozin 10 mg OD) as soon as euvolaemic and stable; beta-blocker, MRA, ARNI once stable and not in cardiogenic shock
Monitor — daily weight, fluid balance, renal function, electrolytes (hypokalaemia, hyponatraemia from diuretics), BP, signs of decongestion (JVP falling, B-lines clearing, weight falling, IVC collapsing)
Renal replacement therapy — if refractory overload (despite high-dose diuretics + thiazide), refractory hyperkalaemia, severe metabolic acidosis, or uraemic complications. Slow continuous ultrafiltration, CVVHDF, or intermittent HD depending on haemodynamic stability

[1]

Stepped approach to diuretic resistance in CRS

Confirm resistance — <100–150 mL/h urine output after an adequate IV loop bolus, or failure to achieve a 1–2 L/day negative balance despite escalating doses.
Exclude correctable causes — high sodium intake (diet, IV fluids, saline flushes), NSAIDs (block diuretic effect), non-adherence, hypotension (low perfusion), hypoalbuminaemia (reduced diuretic delivery to nephron).
Up-titrate the loop diuretic — frusemide up to 200–400 mg/day IV equivalent (bumetanide 1:40, torsemide 1:2 vs frusemide). DOSE trial: high-dose (2.5x home) gave more decongestion than low-dose (1x) with no significant renal harm.[7]
Switch bolus to continuous infusion — smoother natriuresis, may overcome brake phenomena, equivalent efficacy to bolus by DOSE.
Add a thiazide (sequential nephron blockade) — metolazone 2.5–5 mg PO, hydrochlorothiazide 25 mg, or chlorthalidone. Blocks distal Na reabsorption — powerful synergy. Monitor closely: hypokalaemia, hyponatraemia, profound volume depletion, ototoxicity.
Add acetazolamide (250–500 mg) — proximal tubule carbonic anhydrase inhibition, complements the loop + thiazide triple-blockade.
Add or up-titrate MRA (spironolactone/eplerenone) if not hyperkalaemic — blocks aldosterone escape.
Albumin if serum albumin <25 g/L — increases diuretic delivery to the nephron (evidence modest but commonly used).
Vasopressin V2 antagonist (tolvaptan) — for hypervolaemic or euvolaemic hyponatraemia; modest aquaresis.
Ultrafiltration / RRT — only after stepped pharmacological therapy has failed (CARRESS-HF showed pharmacological therapy superior).[4]

Diuretic and decongestion strategies in CRS

Strategy	Mechanism	Indication	Cautions / evidence
High-dose IV loop (frusemide, bumetanide, torsemide)	Inhibit Na-K-2Cl in thick ascending limb — powerful natriuresis	First-line for all congested CRS	Hypokalaemia, hyponatraemia, ototoxicity, alkalosis. DOSE: high-dose (2.5x) superior for decongestion without renal harm.[7]
Continuous infusion	Steady delivery, smoother natriuresis	When bolus ineffective or frequent boluses impractical	DOSE: equivalent to bolus for outcomes; infusion preferred by many units for high doses
Sequential nephron blockade (loop + thiazide)	Block compensatory distal Na reabsorption — synergy	Diuretic resistance on loop alone	VERY potent — monitor K+, Na+, volume daily; ototoxicity
Acetazolamide	Proximal tubule CA inhibition	Triple-blockade for refractory congestion; corrects alkalosis	Metabolic acidosis, hypokalaemia
MRA (spironolactone/eplerenone)	Aldosterone antagonism in collecting duct	Symptomatic HF, diuretic augmentation, K+ preservation	Hyperkalaemia (esp. with ACEi/ARNI), gynaecomastia (spironolactone)
Tolvaptan	Vasopressin V2 antagonist — aquaresis	Hypervolaemic/euvolaemic hyponatraemia	Modest volume effect; costly; hepatotoxicity (in ADPKD doses)
Low-dose dopamine (1–3 mcg/kg/min)	Renal vasodilation (DA1)	Historically for renal protection	ROSE-AHF: NO benefit in ADHF — do NOT use for CRS.[3]
Nesiritide (BNP)	Vasodilation, natriuresis	Historically for ADHF	ROSE-AHF: NO benefit at low dose — do NOT use for CRS.[3]
Ultrafiltration	Mechanical fluid removal via venous access	Refractory overload only (failed stepped diuretics)	CARRESS-HF: MORE adverse events and AKI than stepped pharmacological therapy.[4]
RRT (CVVHDF / HD)	Solute and volume clearance	Refractory overload, hyperkalaemia, acidosis, uraemia	Haemodynamic instability; vascular access; dose for AKI

SGLT2 inhibitors — disease-modifying therapy for cardiorenal syndrome

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most important therapeutic advance in cardiorenal medicine in the last decade. They reduce heart failure hospitalisation, cardiovascular death, and renal progression independent of diabetes status.[8][13]

Mechanisms relevant to CRS:

Osmotic diuresis and natriuresis — modest loop-independent decongestion, reduced preload.
Tubuloglomerular feedback restoration — increased distal Na delivery reactivates afferent arteriolar tone, reducing single-nephron GFR and intraglomerular pressure — renoprotective despite a small creatinine rise at initiation.
Improved cardiac energetics (ketone body utilisation), reduced inflammation and fibrosis, weight loss, lower uric acid, reduced SNS tone. [1]

Initiation in the ICU: do NOT start during acute decompensation with hypovolaemia, ketoacidosis, or perioperative states. Once the patient is euvolaemic, haemodynamically stable, and not in cardiogenic shock, start dapagliflozin 10 mg OD or empagliflozin 10 mg OD as part of the four-pillar GDMT. Hold during acute illness, surgery, or starvation (euglycaemic DKA risk).[12]

Landmark SGLT2 inhibitor trials in cardiorenal disease

Trial (year)	Drug	Population	n	Primary outcome	Effect	Renal signal
DAPA-HF (2019)	Dapagliflozin	HFrEF (EF ≤40%)	4744	CV death or HF hospitalisation	↓ 26%	Slower eGFR decline; ↓ renal composite.[8]
EMPEROR-Reduced (2020)	Empagliflozin	HFrEF	3730	CV death or HF hospitalisation	↓ 25%	↓ 50% renal progression; smaller creatinine rise.[9]
EMPEROR-Preserved (2021)	Empagliflozin	HFpEF (EF >40%)	5988	CV death or HF hospitalisation	↓ 21% (FIRST positive HFpEF trial)	Slower eGFR decline.[10]
DAPA-CKD (2020)	Dapagliflozin	CKD (with/without diabetes)	4304	Sustained eGFR decline, ESRD, renal/CV death	↓ 39%	Renoprotective across CKD causes.[11]
EMPA-KIDNEY (2023)	Empagliflozin	CKD broad	6609	Sustained eGFR decline, ESRD, renal/CV death	↓ 28%	Benefit across eGFR, including low; benefit in non-diabetic CKD

Practical CRS use: dapagliflozin and empagliflozin both reduce HF hospitalisation and renal progression; they can be started in CKD down to eGFR ~20 mL/min/1.73 m² (DAPA-CKD) and even lower per EMPA-KIDNEY. Hold if euglycaemic DKA risk (insulin-dependent diabetes, starvation, surgery) or symptomatic volume depletion. [1]

Exam practice

SAQ — Type 1 cardiorenal syndrome in acute decompensated heart failure

10 minutes · 10 marks

A 72-year-old man with known HFrEF (EF 28%) on oral frusemide 80 mg BD, bisoprolol 5 mg OD, ramipril 5 mg OD and spironolactone 25 mg OD presents after 5 days of progressive dyspnoea, orthopnoea and a 6 kg weight gain. Examination: JVP to the angle of the jaw, bibasal crackles, sacral and pedal oedema to mid-thigh, BP 168/92, HR 102 in atrial fibrillation, RR 28, SpO2 90% on room air. Creatinine 165 μmol/L (baseline 110), eGFR 38 mL/min/1.73 m², K+ 4.8, Na+ 134, NT-proBNP 8 500 ng/L. Bedside ultrasound: bilateral B-lines, dilated IVC without collapse.

[1]

SAQ — Type 2 cardiorenal syndrome with acute-on-chronic kidney injury

10 minutes · 10 marks

A 68-year-old woman with ischaemic HFrEF (EF 25%) and CKD stage 3b (baseline creatinine 180 μmol/L, eGFR 30 mL/min/1.73 m²) on bisoprolol 5 mg OD, ramipril 5 mg OD, spironolactone 12.5 mg OD and empagliflozin 10 mg OD presents with 2 weeks of exertional dyspnoea but no orthopnoea or paroxysmal nocturnal dyspnoea. Examination: JVP raised 4 cm above the sternal angle, trace ankle oedema, clear lung fields, BP 110/65, HR 78 sinus. Creatinine now 240 μmol/L, K+ 5.6 mmol/L, Na+ 136, venous lactate 1.4 mmol/L. Spot urine Na+ 25 mmol/L.

[1]

Clinical pearls

High-yield cardiorenal syndrome points for CICM/FFICM exam

VENOUS CONGESTION drives AKI as much as (or more than) low cardiac output. Elevated CVP → transmitted to renal veins → increased renal interstitial pressure → compressed tubules and peritubular capillaries → reduced GFR. Studies (Mullens): CVP is the STRONGEST haemodynamic predictor of AKI in ADHF (stronger than cardiac output, BP). DECONGESTION is the primary target.[2] }
Worsening renal function during heart failure treatment is common and does NOT always mean harm. 20-40% of ADHF patients have creatinine rise during diuresis. But: those who achieve DECONGESTION (even with creatinine rise) have BETTER outcomes than those who remain congested (with stable creatinine). Don't automatically stop diuretics if creatinine rises — assess overall (are they less oedematous, less breathless?).[13] }
Sequential nephron blockade for diuretic resistance. Loop diuretics (frusemide) alone may fail (compensatory sodium reabsorption in distal tubule). ADD a thiazide (metolazone 2.5-5 mg, or hydrochlorothiazide, or chlorthalidone) → blocks distal tubule → SYNERGISTIC diuresis. VERY potent — monitor for hypokalaemia, hyponatraemia, volume depletion, ototoxicity.[5] }
High-dose loop diuretics: IV dose = 2-2.5x oral dose (bioavailability). Example: oral frusemide 80 mg → IV 40 mg equivalent. For ADHF: start IV frusemide at 1-2.5x HOME dose. DOSE trial: high-dose (2.5x) vs low-dose (1x) — high-dose achieved more fluid loss, faster symptom relief, no significant renal harm. Give as BOLUS or CONTINUOUS INFUSION (equivalent efficacy — bolus easier, infusion smoother).[7] }
Low-dose dopamine and nesiritide do NOT help (negative trials). ROSE-AHF trial: low-dose dopamine (2 mcg/kg/min) and low-dose nesiritide (BNP) did NOT improve decongestion or renal function in ADHF. Don't use them for CRS. Standard therapy (loop diuretics) remains mainstay.[3] }
Ultrafiltration — for refractory overload, not first-line. UNLOAD trial: ultrafiltration removed more fluid than diuretics. BUT CARRESS-HF trial: ultrafiltration WORSE (more adverse events, including AKI, than stepped pharmacological therapy). Use ONLY for refractory overload (failed high-dose diuretics + thiazide). Not first-line. May cause AKI from excessive removal.[4] }
Neurohormonal activation drives vicious cycle. Low output → RAAS activation (angiotensin II → vasoconstriction, aldosterone → sodium retention) + sympathetic activation (vasoconstriction, tachycardia) → worsens heart failure AND renal vasoconstriction → further AKI → worse heart failure. Breaking the cycle: vasodilators (nitrates), ACEi/ARB (once stable), beta-blockers (once stable).[5] }
Hypokalaemia and hyponatraemia from diuretics. Loop diuretics → potassium loss (hypokalaemia — arrhythmia risk), magnesium loss, sodium loss (hyponatraemia — if severe heart failure with high ADH). Monitor daily. Replace K+ (IV or oral), Mg2+. Hyponatraemia: fluid restriction (if hypervolaemic), tolvaptan (vasopressin antagonist — for severe).[5] }
Five types of cardiorenal syndrome (classification). TYPE 1: ACUTE heart failure → AKI (most ICU). TYPE 2: CHRONIC heart failure → CKD. TYPE 3: AKI → acute heart failure (fluid overload, arrhythmia, myocardial ischaemia). TYPE 4: CKD → chronic heart failure (uraemic cardiomyopathy, vascular calcification). TYPE 5: SYSTEMIC disease → both heart and kidney (sepsis, diabetes, amyloid).[6] }
Type 3 CRS (AKI → heart failure) — renal-first. AKI → fluid overload → pulmonary oedema + heart failure. Also: hyperkalaemia → arrhythmia, acidosis → myocardial depression, uraemia → pericarditis. Treatment: treat AKI (fluids if hypovolaemic, dialysis if overloaded), manage heart failure (diuretics — may not work if AKI severe, may need RRT).[1] }
Biomarkers — NGAL, cystatin C for early AKI detection. Creatinine rises 24-48h after kidney injury. NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C rise EARLIER (within hours). May identify AKI before creatinine rises — allowing early intervention. Not yet routine in CRS but emerging.[5] }
Diuretic resistance — stepwise approach. (1) INCREASE loop diuretic dose (up to maximum — frusemide 200-400 mg/day IV). (2) CONTINUOUS INFUSION (vs bolus — smoother, may overcome resistance). (3) ADD thiazide (sequential nephron blockade). (4) ADD potassium-sparing (spironolactone — if not hyperkalaemic). (5) ALBUMIN (if hypoalbuminaemic — increases diuretic delivery to kidney). (6) ULTRAFILTRATION (if all fails). Assess for: non-adherence, high sodium intake, NSAIDs (block diuretics).[5] }
ACEi/ARB in CRS — paradox. ACEi/ARB are DISEASE-MODIFYING for chronic heart failure (improve survival). BUT: in ACUTE decompensation with AKI, they may worsen renal function (reduce GFR by dilating efferent arteriole). TEMPORARILY HOLD during acute crisis (if hypotensive or AKI worsening). RESTART once stable (decongested, renal function improving).[13] }
Prognosis of CRS — poor. AKI in heart failure: mortality 2-3x higher than heart failure alone. Type 1 CRS (acute): hospital mortality 10-20%. Type 2 (chronic): progressive decline. Renal recovery depends on: degree of decongestion, underlying renal disease, avoidance of nephrotoxins. Some recover fully; others progress to CKD.[1] }

Examiner mental map — additional CRS pearls

The 'hemoconcentration' concept — a marker of effective decongestion. A rise in serum total protein or haemoglobin during diuresis reflects hemoconcentration (plasma water removed). Testani et al showed hemoconcentration is associated with HIGHER creatinine but BETTER survival — supporting the paradigm that effective decongestion is beneficial even at the cost of a creatinine rise.[13] }
The cardio-abdominal-renal syndrome — measure bladder pressure in refractory CRS. Severe congestion raises intra-abdominal pressure (IAP) via hepatic and bowel-wall oedema. IAP >12 mmHg (IAH) or >20 mmHg with new organ dysfunction (abdominal compartment syndrome) compresses renal veins and arteries and raises CVP, perpetuating AKI. Measure bladder pressure in any patient with refractory CRS and a tense abdomen — paracentesis or surgical decompression can be rapidly renoprotective.[2] }
Right ventricular failure is the master of CRS. RV failure raises CVP independently of LV function — high CVP is transmitted retrograde to the kidney. A patient with pulmonary hypertension, TR, and a dilated RV will develop CRS even with a normal LV. Treat the RV (diuresis, pulmonary vasodilators, correction of the cause of pulmonary hypertension), not just the LV.[5] }
ADH and hyponatraemia in advanced HF. Severe heart failure → low effective arterial blood volume → non-osmotic ADH release → free water retention → dilutional hyponatraemia. Serum Na <135 mmol/L in HF carries a poor prognosis. Treatment: fluid restriction (1–1.5 L/day), loop diuretic, and for severe symptomatic hyponatraemia a V2 antagonist (tolvaptan 15–30 mg) — but tolvaptan trials (EVEREST) showed no mortality benefit.[5] }
SGLT2 inhibitors cause a small, benign creatinine rise at initiation — don't stop. Within 2–4 weeks of starting dapagliflozin/empagliflozin, eGFR typically drops 2–4 mL/min/1.73 m² (afferent arteriolar effect), then STABILISES with a slower long-term decline than placebo. The initial dip is the mechanism (restored tubuloglomerular feedback) — continue the drug. Stopping it for this dip denies the patient a renoprotective and cardioprotective therapy.[8][11] }
Euglycaemic DKA — the SGLT2 risk that matters in ICU. SGLT2 inhibitors can cause DKA with only mildly raised glucose (<14 mmol/L) — easily missed. Risk factors: insulin-dependent diabetes, recent surgery, starvation, sepsis, pregnancy. Hold SGLT2 inhibitors in any acutely ill ICU patient, around surgery (3–4 days pre-op), and during starvation. Check ketones in any unwell diabetic on an SGLT2 inhibitor with metabolic acidosis.[12] }
The 'spot urine sodium' to assess diuretic adequacy. A urine Na <30 mmol/L on a loop diuretic suggests under-diuresis (the kidney is still avidly retaining sodium) — escalate the dose or add a thiazide. A urine Na >50–70 mmol/L means the kidney is natriuretic — if volume overload persists, the problem is intake (diet, IV fluids, saline flushes), not diuretic dose.[2] }
AF and CRS — bidirectional. Atrial fibrillation both causes (tachycardia-induced cardiomyopathy, loss of atrial kick in diastolic dysfunction) and results from (volume overload, atrial stretch) heart failure — and AF is an independent predictor of AKI in ADHF. Rate control (beta-blocker, digoxin, amiodarone) and anticoagulation (CHA2DS2-VASc) are part of CRS management. Avoid aggressive rhythm control with class I agents in HFrEF.[13] }
Contrast during CRS — risk-minimise, don't refuse. If imaging is essential (coronary angiography for an ACS, CT pulmonary angiography for PE), pre-hydrate (isotonic saline, carefully balanced against congestion), use low- or iso-osmolar contrast at the lowest dose, hold nephrotoxins, and consider N-acetylcysteine or statin loading (modest evidence). The decision is risk-vs-benefit: an untreated STEMI or massive PE is more dangerous to the kidney than the contrast.[1] }
Loop diuretic equivalents — know the conversion. Frusemide 40 mg IV ≈ bumetanide 1 mg IV ≈ torsemide 20 mg PO ≈ ethacrynic acid 50 mg. Torsemide has the most reliable bioavailability and a modest evidence edge over frusemide in HF. Ethacrynic acid is reserved for sulfa-allergy (it is not a sulfonamide).[5] }
Type 5 CRS (sepsis) — the kidney and heart fail together from the same insult. In septic shock, cytokines (TNF-α, IL-6), microcirculatory shunting, mitochondrial dysfunction, and NO-mediated myocardial stunning injure both organs simultaneously. Resuscitation, source control, and early antimicrobials are the therapy; don't chase the creatinine or troponin in isolation — they fall together as the sepsis resolves.[6] }

Red flags

CRS classification and therapy-mismatch red flags

Mislabelling type 5 (sepsis) as type 1 → wrong therapy. In septic CRS, decongestion is secondary to source control and resuscitation; chasing a creatinine with diuretics in a shocked septic patient worsens the kidney.[6]
Mislabelling type 3 (renal-first AKI) as type 1 → wrong therapy. A patient with AKI from obstruction or ATN who develops pulmonary oedema needs the kidney fixed (relieve obstruction, RRT), not loop diuretics which may worsen the kidney.
Stopping loop diuretics for a creatinine rise in a still-congested patient → harms. Continue decongestion; the prognosis is driven by achieving euvolaemia, not by the creatinine number.[13]
Using low-dose dopamine or nesiritide for 'renal protection' → no benefit (ROSE-AHF), adds harm and polypharmacy.[3]
First-line ultrafiltration for congestion → CARRESS-HF showed worse outcomes than stepped pharmacological therapy.[4]
Forgetting the RV and the abdomen → RV failure and intra-abdominal hypertension raise CVP independent of LV function; a tense abdomen or a dilated RV will perpetuate AKI until addressed.[2]

Prognosis and key trials

CARRESS-HF trial (Bart 2012) — ultrafiltration vs pharmacological therapy

RCT: 188 patients with ADHF + worsening renal function + persistent congestion. Stepped pharmacological therapy (high-dose loop + thiazide) vs ultrafiltration.

Primary outcome (weight loss at 96h): similar (5.7 kg pharmacological vs 5.1 kg ultrafiltration — no difference)
Creatinine change: WORSE with ultrafiltration (+0.23 mg/dL vs -0.04 mg/dL, p=0.003)
Serious adverse events: HIGHER with ultrafiltration (72% vs 57%, p=0.03)
CONCLUSION: Pharmacological therapy (stepped diuretics) SUPERIOR to ultrafiltration for CRS. Ultrafiltration reserved for refractory cases only.[4]

DOSE trial (Felker 2011): high-dose (2.5x) vs low-dose (1x) loop diuretic; bolus vs continuous infusion. High-dose: more fluid loss, faster symptom relief, similar renal function. HIGH-DOSE preferred; bolus and infusion equivalent.[7] ROSE-AHF (Chen 2013): low-dose dopamine and low-dose nesiritide did NOT improve renal function or decongestion in ADHF with renal dysfunction. Don't use either for CRS.[3]

SGLT2 inhibitor trials — the disease-modifying breakthrough

DAPA-HF (2019) — dapagliflozin vs placebo in HFrEF (with and without diabetes): ↓ primary outcome (CV death or HF hospitalisation) 26%, ↓ all-cause mortality 17%, slower eGFR decline.[8]

EMPEROR-Reduced (2020) — empagliflozin in HFrEF: ↓ primary outcome 25%, ↓ renal progression 50%, smaller creatinine rise than placebo.[9]

EMPEROR-Preserved (2021) — empagliflozin in HFpEF: ↓ HF hospitalisation 29%, FIRST positive HFpEF trial; slower eGFR decline.[10]

DAPA-CKD (2020) — dapagliflozin in CKD (with and without diabetes): ↓ composite renal / CV death 39%, benefit down to eGFR 25 mL/min/1.73 m², benefit independent of diabetes.[11]

EMPA-KIDNEY (2023) — empagliflozin in broad CKD (including low eGFR ~20 and non-diabetic): ↓ composite renal / CV death 28%. [1]

Take-home for CRS: SGLT2 inhibitors are the first drug class to simultaneously reduce heart failure events AND renal progression in HFrEF, HFpEF, and CKD — independent of diabetes. Start as part of GDMT once the patient is stable, not during the acute crisis.[12]

Mechanism and supportive trials

UNLOAD (2008) — ultrafiltration removed more fluid than diuretics at 48h; subsequently superseded by CARRESS-HF for safety. [1]

ESCAPE (2005) — pulmonary artery catheter-guided therapy did NOT improve outcomes in ADHF, but the dataset (Mullens analyses) established that CVP is the strongest haemodynamic predictor of AKI in ADHF.[2]

EVEREST (2007) — tolvaptan (V2 antagonist) for hypervolaemic/euvolaemic hyponatraemia in HF: aquaresis and Na correction, but no mortality benefit. [1]

SECRET of CRS — the four convergent pathophysiology pathways (venous congestion, low forward flow, RAAS/SNS activation, inflammation) explain why decongestion + disease-modifying neurohormonal therapy + SGLT2 + source control together improve outcomes, while isolated 'renal-protective' drugs (dopamine, nesiritide) fail.[1][13]

AnswerCard summary

The one-paragraph exam answer for type 1 CRS

Cardiorenal syndrome is a disorder of the heart and kidneys in which acute or chronic dysfunction of one organ causes dysfunction of the other. The five types are type 1 (acute HF → AKI, the ICU prototype), type 2 (chronic HF → CKD), type 3 (AKI → acute HF), type 4 (CKD → chronic HF), and type 5 (systemic disease → both). In type 1 the dominant mechanism is venous congestion — raised CVP transmitted retrograde to the renal veins raises interstitial pressure and compresses the tubules and peritubular capillaries, reducing GFR; RAAS/SNS activation, low forward flow, intra-abdominal hypertension, and inflammation amplify injury. Management is decongestion (high-dose IV loop diuretic at 2–2.5x the home dose, escalated to sequential nephron blockade with metolazone if resistant), vasodilators (nitrates) if hypertensive, inotropes if hypoperfused, avoidance of nephrotoxins, and SGLT2 inhibitors (dapagliflozin, empagliflozin) started once stable as disease-modifying therapy. A creatinine rise during effective decongestion is acceptable and prognostically favourable. Ultrafiltration (CARRESS-HF) is not first-line — stepped pharmacological therapy is superior. Low-dose dopamine and nesiritide (ROSE-AHF) do not help. Prognosis is poor, with two- to three-fold higher mortality than HF alone.[1][2][4][8]

References

[1]Rangaswami J, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association Circulation, 2019.PMID 30852913
[2]Mullens W, et al. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, 2020.PMID 31908120
[3]Chen HH, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial JAMA, 2013.PMID 24247300
[4]Bart BA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome N Engl J Med, 2012.PMID 23131078
[5]Damman K, et al. The kidney in heart failure: an update Eur Heart J, 2015.PMID 25838436
[6]Ronco C, et al. Cardio-renal syndromes: a systematic approach for consensus definition and classification Heart Fail Rev, 2012.PMID 21197571
[7]Felker GM, et al. Diuretic strategies in patients with acute decompensated heart failure N Engl J Med, 2011.PMID 21366472
[8]McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction N Engl J Med, 2019.PMID 31535829
[9]Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure N Engl J Med, 2020.PMID 32865377
[10]Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction N Engl J Med, 2021.PMID 34449189
[11]Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med, 2020.PMID 32970396
[12]McCallum W, et al. Updates in Cardiorenal Syndrome Med Clin North Am, 2023.PMID 37258013
[13]Damman K, et al. Cardiorenal interactions in heart failure: insights from recent therapeutic advances Cardiovasc Res, 2024.PMID 37364186

[1]

The five types of cardiorenal syndrome

The five types of cardiorenal syndrome (Ronco/Rangaswami classification)

Type	Name	Primary insult	Secondary effect	Setting	Typical ICU relevance
1	Acute cardiorenal	Acute heart failure / ACS / flash pulmonary oedema	AKI develops hours-days	ICU, ED, CCU	Highest — most encountered in ICU
2	Chronic cardiorenal	Chronic heart failure (HFrEF/HFpEF)	Progressive CKD	Outpatient, cardiology	Moderate — seen during exacerbations
3	Acute renocardial	AKI (contrast nephropathy, ATN, obstruction)	Acute heart failure (volume, K+, acidosis, uraemia)	ICU, nephrology	High — common in ICU AKI
4	Chronic renocardial	CKD / ESRD	Chronic heart failure (uraemic cardiomyopathy, LVH, vascular calcification)	Renal clinic, dialysis unit	Moderate — dialysis patients in ICU
5	Secondary (systemic)	Systemic disease (sepsis, diabetes, amyloid, SLE, cirrhosis)	Simultaneous heart AND kidney dysfunction	ICU, multisystem disease	High — sepsis is the prototype

[1]

Pathophysiology in depth

1. Venous congestion — the dominant driver in decompensated HF

2. Low forward flow — reduced renal perfusion

3. Neurohormonal activation — the vicious cycle

Reduced renal perfusion and sympathetic sensing trigger the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS):

Angiotensin II → efferent arteriolar vasoconstriction (maintains GFR acutely — the basis for the ACEi/ARB creatinine rise), systemic vasoconstriction, aldosterone release, sodium retention, inflammation and fibrosis.
Aldosterone → distal sodium reabsorption, potassium/magnesium loss, myocardial fibrosis.
Sympathetic activation → vasoconstriction, tachycardia, renin release, arrhythmias. [1]

4. Inflammation, oxidative stress and endothelial dysfunction

5. Intra-abdominal hypertension (IAH) and the cardio-abdominal-renal syndrome

Venous congestion vs low forward flow — two mechanisms, different therapy

Feature	Venous congestion dominant	Low forward flow dominant
Typical patient	ADHF, volume overload, raised JVP, oedema, hepatomegaly	Cardiogenic shock, cool peripheries, oliguria, low CO
CVP	High (>12–14 mmHg)	Variable — may be low or normal
Cardiac output	Preserved or high (warm, wet)	Low (cold, dry or cold, wet)
Blood pressure	Often high	Often low
Primary therapy	Decongestion — high-dose loop ± thiazide, nitrates	Restore output — inotrope, vasopressor, MCS
Creatinine on diuresis	May rise — continue if decongesting	Worsens with low flow — fix output
Prognostic marker	CVP is the strongest predictor of AKI	MAP, lactate, mixed venous saturation

[1]

Clinical assessment

Bedside assessment of congestion:

Jugular venous pressure — the single most useful bedside sign. Raised JVP = venous congestion.
Lung auscultation — crackles (but crackles may be absent in chronic HF).
Peripheral oedema, sacral oedema, ascites.
Hepatomegaly, hepatojugular reflux.
Lung ultrasound — B-lines (comet-tail artefacts) quantify extravascular lung water; multiple bilateral B-lines = interstitial pulmonary oedema.
Point-of-care echo — IVC size and collapsibility (a plethoric, non-collapsing IVC = high CVP); right heart assessment for pulmonary hypertension, RV failure, TR; LV systolic and diastolic function.
Daily weights — the most sensitive bedside measure of net fluid balance.
Hemodynamic monitoring — CVP (central line), arterial line for MAP; advanced monitors (PiCCO, pulmonary artery catheter) when peripheral perfusion or cardiac output is in question. [1]

Laboratory and imaging:

Urea, creatinine, eGFR, electrolytes (K+, Na+, Mg2+, phosphate), venous blood gas (lactate, acidosis).
Troponin (myocardial injury), NT-proBNP/BNP (heart failure severity — but BNP rises with renal dysfunction alone).
Urine sodium (low <30 mmol/L on diuretics suggests under-diuresis; FENa if pre-renal vs ATN unclear).
Urinalysis — bland in CRS; casts/proteinuria suggest intrinsic renal disease (type 3 or concurrent).
Echocardiography — EF, diastolic function, RV size and function, valvular lesions, pericardial effusion, IVC.
Renal ultrasound — to exclude obstruction (especially type 3), assess kidney size/corticomedullary differentiation for chronicity. [1]

Management of acute cardiorenal syndrome

Management of acute cardiorenal syndrome (type 1)

Assess volume status and perfusion — clinical (JVP, oedema, crackles, hepatomegaly, peripheral temperature, capillary refill, urine output), ultrasound (IVC, B-lines), haemodynamics (CVP, MAP, cardiac output if monitored). Classify as WARM/WET, WARM/DRY, COLD/WET, COLD/DRY.
Decongest (primary target for wet patients) — HIGH-DOSE loop diuretics (frusemide IV — 2-2.5x oral dose). If inadequate: ADD thiazide (metolazone/hydrochlorothiazide — sequential nephron blockade). TARGET: 2-3 L negative balance/day (or adequate urine output). Monitor renal function — may rise, continue if congested
Optimise cardiac output (for cold patients) — if low output (cardiogenic shock): inotropes (dobutamine, milrinone). Vasopressors (noradrenaline) if MAP <65. Vasodilators (GTN infusion) if hypertensive and warm. Mechanical circulatory support (IABP, Impella, VA-ECMO) if refractory shock. Avoid hypotension (worsens renal perfusion)
Avoid nephrotoxins — STOP NSAIDs, ACEi/ARB/ARNI (temporarily if hypotensive), contrast (use pre-procedural hydration if unavoidable), aminoglycosides, iodinated contrast
Treat electrolyte derangements — replace K+ (IV/oral), Mg2+; manage hyponatraemia (fluid restriction, tolvaptan for severe); correct acidosis
Start disease-modifying therapy once stable — SGLT2 inhibitor (dapagliflozin 10 mg OD) as soon as euvolaemic and stable; beta-blocker, MRA, ARNI once stable and not in cardiogenic shock
Monitor — daily weight, fluid balance, renal function, electrolytes (hypokalaemia, hyponatraemia from diuretics), BP, signs of decongestion (JVP falling, B-lines clearing, weight falling, IVC collapsing)
Renal replacement therapy — if refractory overload (despite high-dose diuretics + thiazide), refractory hyperkalaemia, severe metabolic acidosis, or uraemic complications. Slow continuous ultrafiltration, CVVHDF, or intermittent HD depending on haemodynamic stability

[1]

Stepped approach to diuretic resistance in CRS

Confirm resistance — <100–150 mL/h urine output after an adequate IV loop bolus, or failure to achieve a 1–2 L/day negative balance despite escalating doses.
Exclude correctable causes — high sodium intake (diet, IV fluids, saline flushes), NSAIDs (block diuretic effect), non-adherence, hypotension (low perfusion), hypoalbuminaemia (reduced diuretic delivery to nephron).
Up-titrate the loop diuretic — frusemide up to 200–400 mg/day IV equivalent (bumetanide 1:40, torsemide 1:2 vs frusemide). DOSE trial: high-dose (2.5x home) gave more decongestion than low-dose (1x) with no significant renal harm.[7]
Switch bolus to continuous infusion — smoother natriuresis, may overcome brake phenomena, equivalent efficacy to bolus by DOSE.
Add a thiazide (sequential nephron blockade) — metolazone 2.5–5 mg PO, hydrochlorothiazide 25 mg, or chlorthalidone. Blocks distal Na reabsorption — powerful synergy. Monitor closely: hypokalaemia, hyponatraemia, profound volume depletion, ototoxicity.
Add acetazolamide (250–500 mg) — proximal tubule carbonic anhydrase inhibition, complements the loop + thiazide triple-blockade.
Add or up-titrate MRA (spironolactone/eplerenone) if not hyperkalaemic — blocks aldosterone escape.
Albumin if serum albumin <25 g/L — increases diuretic delivery to the nephron (evidence modest but commonly used).
Vasopressin V2 antagonist (tolvaptan) — for hypervolaemic or euvolaemic hyponatraemia; modest aquaresis.
Ultrafiltration / RRT — only after stepped pharmacological therapy has failed (CARRESS-HF showed pharmacological therapy superior).[4]

Diuretic and decongestion strategies in CRS

Strategy	Mechanism	Indication	Cautions / evidence
High-dose IV loop (frusemide, bumetanide, torsemide)	Inhibit Na-K-2Cl in thick ascending limb — powerful natriuresis	First-line for all congested CRS	Hypokalaemia, hyponatraemia, ototoxicity, alkalosis. DOSE: high-dose (2.5x) superior for decongestion without renal harm.[7]
Continuous infusion	Steady delivery, smoother natriuresis	When bolus ineffective or frequent boluses impractical	DOSE: equivalent to bolus for outcomes; infusion preferred by many units for high doses
Sequential nephron blockade (loop + thiazide)	Block compensatory distal Na reabsorption — synergy	Diuretic resistance on loop alone	VERY potent — monitor K+, Na+, volume daily; ototoxicity
Acetazolamide	Proximal tubule CA inhibition	Triple-blockade for refractory congestion; corrects alkalosis	Metabolic acidosis, hypokalaemia
MRA (spironolactone/eplerenone)	Aldosterone antagonism in collecting duct	Symptomatic HF, diuretic augmentation, K+ preservation	Hyperkalaemia (esp. with ACEi/ARNI), gynaecomastia (spironolactone)
Tolvaptan	Vasopressin V2 antagonist — aquaresis	Hypervolaemic/euvolaemic hyponatraemia	Modest volume effect; costly; hepatotoxicity (in ADPKD doses)
Low-dose dopamine (1–3 mcg/kg/min)	Renal vasodilation (DA1)	Historically for renal protection	ROSE-AHF: NO benefit in ADHF — do NOT use for CRS.[3]
Nesiritide (BNP)	Vasodilation, natriuresis	Historically for ADHF	ROSE-AHF: NO benefit at low dose — do NOT use for CRS.[3]
Ultrafiltration	Mechanical fluid removal via venous access	Refractory overload only (failed stepped diuretics)	CARRESS-HF: MORE adverse events and AKI than stepped pharmacological therapy.[4]
RRT (CVVHDF / HD)	Solute and volume clearance	Refractory overload, hyperkalaemia, acidosis, uraemia	Haemodynamic instability; vascular access; dose for AKI

SGLT2 inhibitors — disease-modifying therapy for cardiorenal syndrome

Mechanisms relevant to CRS:

Osmotic diuresis and natriuresis — modest loop-independent decongestion, reduced preload.
Tubuloglomerular feedback restoration — increased distal Na delivery reactivates afferent arteriolar tone, reducing single-nephron GFR and intraglomerular pressure — renoprotective despite a small creatinine rise at initiation.
Improved cardiac energetics (ketone body utilisation), reduced inflammation and fibrosis, weight loss, lower uric acid, reduced SNS tone. [1]

Landmark SGLT2 inhibitor trials in cardiorenal disease

Trial (year)	Drug	Population	n	Primary outcome	Effect	Renal signal
DAPA-HF (2019)	Dapagliflozin	HFrEF (EF ≤40%)	4744	CV death or HF hospitalisation	↓ 26%	Slower eGFR decline; ↓ renal composite.[8]
EMPEROR-Reduced (2020)	Empagliflozin	HFrEF	3730	CV death or HF hospitalisation	↓ 25%	↓ 50% renal progression; smaller creatinine rise.[9]
EMPEROR-Preserved (2021)	Empagliflozin	HFpEF (EF >40%)	5988	CV death or HF hospitalisation	↓ 21% (FIRST positive HFpEF trial)	Slower eGFR decline.[10]
DAPA-CKD (2020)	Dapagliflozin	CKD (with/without diabetes)	4304	Sustained eGFR decline, ESRD, renal/CV death	↓ 39%	Renoprotective across CKD causes.[11]
EMPA-KIDNEY (2023)	Empagliflozin	CKD broad	6609	Sustained eGFR decline, ESRD, renal/CV death	↓ 28%	Benefit across eGFR, including low; benefit in non-diabetic CKD

Exam practice

SAQ — Type 1 cardiorenal syndrome in acute decompensated heart failure

10 minutes · 10 marks

[1]

SAQ — Type 2 cardiorenal syndrome with acute-on-chronic kidney injury

10 minutes · 10 marks

[1]

Clinical pearls

High-yield cardiorenal syndrome points for CICM/FFICM exam

VENOUS CONGESTION drives AKI as much as (or more than) low cardiac output. Elevated CVP → transmitted to renal veins → increased renal interstitial pressure → compressed tubules and peritubular capillaries → reduced GFR. Studies (Mullens): CVP is the STRONGEST haemodynamic predictor of AKI in ADHF (stronger than cardiac output, BP). DECONGESTION is the primary target.[2] }
Worsening renal function during heart failure treatment is common and does NOT always mean harm. 20-40% of ADHF patients have creatinine rise during diuresis. But: those who achieve DECONGESTION (even with creatinine rise) have BETTER outcomes than those who remain congested (with stable creatinine). Don't automatically stop diuretics if creatinine rises — assess overall (are they less oedematous, less breathless?).[13] }
Sequential nephron blockade for diuretic resistance. Loop diuretics (frusemide) alone may fail (compensatory sodium reabsorption in distal tubule). ADD a thiazide (metolazone 2.5-5 mg, or hydrochlorothiazide, or chlorthalidone) → blocks distal tubule → SYNERGISTIC diuresis. VERY potent — monitor for hypokalaemia, hyponatraemia, volume depletion, ototoxicity.[5] }
High-dose loop diuretics: IV dose = 2-2.5x oral dose (bioavailability). Example: oral frusemide 80 mg → IV 40 mg equivalent. For ADHF: start IV frusemide at 1-2.5x HOME dose. DOSE trial: high-dose (2.5x) vs low-dose (1x) — high-dose achieved more fluid loss, faster symptom relief, no significant renal harm. Give as BOLUS or CONTINUOUS INFUSION (equivalent efficacy — bolus easier, infusion smoother).[7] }
Low-dose dopamine and nesiritide do NOT help (negative trials). ROSE-AHF trial: low-dose dopamine (2 mcg/kg/min) and low-dose nesiritide (BNP) did NOT improve decongestion or renal function in ADHF. Don't use them for CRS. Standard therapy (loop diuretics) remains mainstay.[3] }
Ultrafiltration — for refractory overload, not first-line. UNLOAD trial: ultrafiltration removed more fluid than diuretics. BUT CARRESS-HF trial: ultrafiltration WORSE (more adverse events, including AKI, than stepped pharmacological therapy). Use ONLY for refractory overload (failed high-dose diuretics + thiazide). Not first-line. May cause AKI from excessive removal.[4] }
Neurohormonal activation drives vicious cycle. Low output → RAAS activation (angiotensin II → vasoconstriction, aldosterone → sodium retention) + sympathetic activation (vasoconstriction, tachycardia) → worsens heart failure AND renal vasoconstriction → further AKI → worse heart failure. Breaking the cycle: vasodilators (nitrates), ACEi/ARB (once stable), beta-blockers (once stable).[5] }
Hypokalaemia and hyponatraemia from diuretics. Loop diuretics → potassium loss (hypokalaemia — arrhythmia risk), magnesium loss, sodium loss (hyponatraemia — if severe heart failure with high ADH). Monitor daily. Replace K+ (IV or oral), Mg2+. Hyponatraemia: fluid restriction (if hypervolaemic), tolvaptan (vasopressin antagonist — for severe).[5] }
Five types of cardiorenal syndrome (classification). TYPE 1: ACUTE heart failure → AKI (most ICU). TYPE 2: CHRONIC heart failure → CKD. TYPE 3: AKI → acute heart failure (fluid overload, arrhythmia, myocardial ischaemia). TYPE 4: CKD → chronic heart failure (uraemic cardiomyopathy, vascular calcification). TYPE 5: SYSTEMIC disease → both heart and kidney (sepsis, diabetes, amyloid).[6] }
Type 3 CRS (AKI → heart failure) — renal-first. AKI → fluid overload → pulmonary oedema + heart failure. Also: hyperkalaemia → arrhythmia, acidosis → myocardial depression, uraemia → pericarditis. Treatment: treat AKI (fluids if hypovolaemic, dialysis if overloaded), manage heart failure (diuretics — may not work if AKI severe, may need RRT).[1] }
Biomarkers — NGAL, cystatin C for early AKI detection. Creatinine rises 24-48h after kidney injury. NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C rise EARLIER (within hours). May identify AKI before creatinine rises — allowing early intervention. Not yet routine in CRS but emerging.[5] }
Diuretic resistance — stepwise approach. (1) INCREASE loop diuretic dose (up to maximum — frusemide 200-400 mg/day IV). (2) CONTINUOUS INFUSION (vs bolus — smoother, may overcome resistance). (3) ADD thiazide (sequential nephron blockade). (4) ADD potassium-sparing (spironolactone — if not hyperkalaemic). (5) ALBUMIN (if hypoalbuminaemic — increases diuretic delivery to kidney). (6) ULTRAFILTRATION (if all fails). Assess for: non-adherence, high sodium intake, NSAIDs (block diuretics).[5] }
ACEi/ARB in CRS — paradox. ACEi/ARB are DISEASE-MODIFYING for chronic heart failure (improve survival). BUT: in ACUTE decompensation with AKI, they may worsen renal function (reduce GFR by dilating efferent arteriole). TEMPORARILY HOLD during acute crisis (if hypotensive or AKI worsening). RESTART once stable (decongested, renal function improving).[13] }
Prognosis of CRS — poor. AKI in heart failure: mortality 2-3x higher than heart failure alone. Type 1 CRS (acute): hospital mortality 10-20%. Type 2 (chronic): progressive decline. Renal recovery depends on: degree of decongestion, underlying renal disease, avoidance of nephrotoxins. Some recover fully; others progress to CKD.[1] }

Examiner mental map — additional CRS pearls

The 'hemoconcentration' concept — a marker of effective decongestion. A rise in serum total protein or haemoglobin during diuresis reflects hemoconcentration (plasma water removed). Testani et al showed hemoconcentration is associated with HIGHER creatinine but BETTER survival — supporting the paradigm that effective decongestion is beneficial even at the cost of a creatinine rise.[13] }
The cardio-abdominal-renal syndrome — measure bladder pressure in refractory CRS. Severe congestion raises intra-abdominal pressure (IAP) via hepatic and bowel-wall oedema. IAP >12 mmHg (IAH) or >20 mmHg with new organ dysfunction (abdominal compartment syndrome) compresses renal veins and arteries and raises CVP, perpetuating AKI. Measure bladder pressure in any patient with refractory CRS and a tense abdomen — paracentesis or surgical decompression can be rapidly renoprotective.[2] }
Right ventricular failure is the master of CRS. RV failure raises CVP independently of LV function — high CVP is transmitted retrograde to the kidney. A patient with pulmonary hypertension, TR, and a dilated RV will develop CRS even with a normal LV. Treat the RV (diuresis, pulmonary vasodilators, correction of the cause of pulmonary hypertension), not just the LV.[5] }
ADH and hyponatraemia in advanced HF. Severe heart failure → low effective arterial blood volume → non-osmotic ADH release → free water retention → dilutional hyponatraemia. Serum Na <135 mmol/L in HF carries a poor prognosis. Treatment: fluid restriction (1–1.5 L/day), loop diuretic, and for severe symptomatic hyponatraemia a V2 antagonist (tolvaptan 15–30 mg) — but tolvaptan trials (EVEREST) showed no mortality benefit.[5] }
SGLT2 inhibitors cause a small, benign creatinine rise at initiation — don't stop. Within 2–4 weeks of starting dapagliflozin/empagliflozin, eGFR typically drops 2–4 mL/min/1.73 m² (afferent arteriolar effect), then STABILISES with a slower long-term decline than placebo. The initial dip is the mechanism (restored tubuloglomerular feedback) — continue the drug. Stopping it for this dip denies the patient a renoprotective and cardioprotective therapy.[8][11] }
Euglycaemic DKA — the SGLT2 risk that matters in ICU. SGLT2 inhibitors can cause DKA with only mildly raised glucose (<14 mmol/L) — easily missed. Risk factors: insulin-dependent diabetes, recent surgery, starvation, sepsis, pregnancy. Hold SGLT2 inhibitors in any acutely ill ICU patient, around surgery (3–4 days pre-op), and during starvation. Check ketones in any unwell diabetic on an SGLT2 inhibitor with metabolic acidosis.[12] }
The 'spot urine sodium' to assess diuretic adequacy. A urine Na <30 mmol/L on a loop diuretic suggests under-diuresis (the kidney is still avidly retaining sodium) — escalate the dose or add a thiazide. A urine Na >50–70 mmol/L means the kidney is natriuretic — if volume overload persists, the problem is intake (diet, IV fluids, saline flushes), not diuretic dose.[2] }
AF and CRS — bidirectional. Atrial fibrillation both causes (tachycardia-induced cardiomyopathy, loss of atrial kick in diastolic dysfunction) and results from (volume overload, atrial stretch) heart failure — and AF is an independent predictor of AKI in ADHF. Rate control (beta-blocker, digoxin, amiodarone) and anticoagulation (CHA2DS2-VASc) are part of CRS management. Avoid aggressive rhythm control with class I agents in HFrEF.[13] }
Contrast during CRS — risk-minimise, don't refuse. If imaging is essential (coronary angiography for an ACS, CT pulmonary angiography for PE), pre-hydrate (isotonic saline, carefully balanced against congestion), use low- or iso-osmolar contrast at the lowest dose, hold nephrotoxins, and consider N-acetylcysteine or statin loading (modest evidence). The decision is risk-vs-benefit: an untreated STEMI or massive PE is more dangerous to the kidney than the contrast.[1] }
Loop diuretic equivalents — know the conversion. Frusemide 40 mg IV ≈ bumetanide 1 mg IV ≈ torsemide 20 mg PO ≈ ethacrynic acid 50 mg. Torsemide has the most reliable bioavailability and a modest evidence edge over frusemide in HF. Ethacrynic acid is reserved for sulfa-allergy (it is not a sulfonamide).[5] }
Type 5 CRS (sepsis) — the kidney and heart fail together from the same insult. In septic shock, cytokines (TNF-α, IL-6), microcirculatory shunting, mitochondrial dysfunction, and NO-mediated myocardial stunning injure both organs simultaneously. Resuscitation, source control, and early antimicrobials are the therapy; don't chase the creatinine or troponin in isolation — they fall together as the sepsis resolves.[6] }

Red flags

CRS classification and therapy-mismatch red flags

Mislabelling type 5 (sepsis) as type 1 → wrong therapy. In septic CRS, decongestion is secondary to source control and resuscitation; chasing a creatinine with diuretics in a shocked septic patient worsens the kidney.[6]
Mislabelling type 3 (renal-first AKI) as type 1 → wrong therapy. A patient with AKI from obstruction or ATN who develops pulmonary oedema needs the kidney fixed (relieve obstruction, RRT), not loop diuretics which may worsen the kidney.
Stopping loop diuretics for a creatinine rise in a still-congested patient → harms. Continue decongestion; the prognosis is driven by achieving euvolaemia, not by the creatinine number.[13]
Using low-dose dopamine or nesiritide for 'renal protection' → no benefit (ROSE-AHF), adds harm and polypharmacy.[3]
First-line ultrafiltration for congestion → CARRESS-HF showed worse outcomes than stepped pharmacological therapy.[4]
Forgetting the RV and the abdomen → RV failure and intra-abdominal hypertension raise CVP independent of LV function; a tense abdomen or a dilated RV will perpetuate AKI until addressed.[2]

Prognosis and key trials

CARRESS-HF trial (Bart 2012) — ultrafiltration vs pharmacological therapy

RCT: 188 patients with ADHF + worsening renal function + persistent congestion. Stepped pharmacological therapy (high-dose loop + thiazide) vs ultrafiltration.

Primary outcome (weight loss at 96h): similar (5.7 kg pharmacological vs 5.1 kg ultrafiltration — no difference)
Creatinine change: WORSE with ultrafiltration (+0.23 mg/dL vs -0.04 mg/dL, p=0.003)
Serious adverse events: HIGHER with ultrafiltration (72% vs 57%, p=0.03)
CONCLUSION: Pharmacological therapy (stepped diuretics) SUPERIOR to ultrafiltration for CRS. Ultrafiltration reserved for refractory cases only.[4]

SGLT2 inhibitor trials — the disease-modifying breakthrough

DAPA-HF (2019) — dapagliflozin vs placebo in HFrEF (with and without diabetes): ↓ primary outcome (CV death or HF hospitalisation) 26%, ↓ all-cause mortality 17%, slower eGFR decline.[8]

EMPEROR-Reduced (2020) — empagliflozin in HFrEF: ↓ primary outcome 25%, ↓ renal progression 50%, smaller creatinine rise than placebo.[9]

EMPEROR-Preserved (2021) — empagliflozin in HFpEF: ↓ HF hospitalisation 29%, FIRST positive HFpEF trial; slower eGFR decline.[10]

DAPA-CKD (2020) — dapagliflozin in CKD (with and without diabetes): ↓ composite renal / CV death 39%, benefit down to eGFR 25 mL/min/1.73 m², benefit independent of diabetes.[11]

EMPA-KIDNEY (2023) — empagliflozin in broad CKD (including low eGFR ~20 and non-diabetic): ↓ composite renal / CV death 28%. [1]

Mechanism and supportive trials

UNLOAD (2008) — ultrafiltration removed more fluid than diuretics at 48h; subsequently superseded by CARRESS-HF for safety. [1]

EVEREST (2007) — tolvaptan (V2 antagonist) for hypervolaemic/euvolaemic hyponatraemia in HF: aquaresis and Na correction, but no mortality benefit. [1]

AnswerCard summary

The one-paragraph exam answer for type 1 CRS

References

[1]Rangaswami J, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association Circulation, 2019.PMID 30852913
[2]Mullens W, et al. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, 2020.PMID 31908120
[3]Chen HH, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial JAMA, 2013.PMID 24247300
[4]Bart BA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome N Engl J Med, 2012.PMID 23131078
[5]Damman K, et al. The kidney in heart failure: an update Eur Heart J, 2015.PMID 25838436
[6]Ronco C, et al. Cardio-renal syndromes: a systematic approach for consensus definition and classification Heart Fail Rev, 2012.PMID 21197571
[7]Felker GM, et al. Diuretic strategies in patients with acute decompensated heart failure N Engl J Med, 2011.PMID 21366472
[8]McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction N Engl J Med, 2019.PMID 31535829
[9]Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure N Engl J Med, 2020.PMID 32865377
[10]Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction N Engl J Med, 2021.PMID 34449189
[11]Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med, 2020.PMID 32970396
[12]McCallum W, et al. Updates in Cardiorenal Syndrome Med Clin North Am, 2023.PMID 37258013
[13]Damman K, et al. Cardiorenal interactions in heart failure: insights from recent therapeutic advances Cardiovasc Res, 2024.PMID 37364186

Your progress

The five types of cardiorenal syndrome

Pathophysiology in depth

1. Venous congestion — the dominant driver in decompensated HF

2. Low forward flow — reduced renal perfusion

3. Neurohormonal activation — the vicious cycle

4. Inflammation, oxidative stress and endothelial dysfunction

5. Intra-abdominal hypertension (IAH) and the cardio-abdominal-renal syndrome

Clinical assessment

Management of acute cardiorenal syndrome

SGLT2 inhibitors — disease-modifying therapy for cardiorenal syndrome

Exam practice

SAQ — Type 1 cardiorenal syndrome in acute decompensated heart failure

SAQ — Type 2 cardiorenal syndrome with acute-on-chronic kidney injury

Clinical pearls

Red flags

Prognosis and key trials

CARRESS-HF trial (Bart 2012) — ultrafiltration vs pharmacological therapy

SGLT2 inhibitor trials — the disease-modifying breakthrough

Mechanism and supportive trials

AnswerCard summary

References

Your progress

The five types of cardiorenal syndrome

Pathophysiology in depth

1. Venous congestion — the dominant driver in decompensated HF

2. Low forward flow — reduced renal perfusion

3. Neurohormonal activation — the vicious cycle

4. Inflammation, oxidative stress and endothelial dysfunction

5. Intra-abdominal hypertension (IAH) and the cardio-abdominal-renal syndrome

Clinical assessment

Management of acute cardiorenal syndrome

SGLT2 inhibitors — disease-modifying therapy for cardiorenal syndrome

Exam practice

SAQ — Type 1 cardiorenal syndrome in acute decompensated heart failure

SAQ — Type 2 cardiorenal syndrome with acute-on-chronic kidney injury

Clinical pearls

Red flags

Prognosis and key trials

CARRESS-HF trial (Bart 2012) — ultrafiltration vs pharmacological therapy

SGLT2 inhibitor trials — the disease-modifying breakthrough

Mechanism and supportive trials

AnswerCard summary

References